Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Armuzzi

Showing results (291-300 of 320) with videos related to

Pageof 32
Sort By:
Journal of Clinical Medicine|January 8, 2025
Real-World Effectiveness and Safety of Selective JAK Inhibitors in Ulcerative Colitis and Crohn's Disease: A Retrospective, Multicentre StudyBernadett Farkas, Talat Bessissow, Jimmy K Limdi, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 21, 2013
Adalimumab in active ulcerative colitis: a "real-life" observational study, Alessandro Armuzzi, Livia Biancone, et al.
JAMA|July 22, 2024
Risankizumab for Ulcerative Colitis: Two Randomized Clinical TrialsEdouard Louis, Stefan Schreiber, Remo Panaccione, et al.
United European Gastroenterology Journal|November 18, 2020
Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD studyDaniela Pugliese, Giuseppe Privitera, Francesca Rogai, et al.
The American Journal of Gastroenterology|April 25, 2022
An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha InhibitorsSara Onali, Daniela Pugliese, Flavio Andrea Caprioli, et al.
European Journal of Clinical Investigation|July 9, 2024
An international multicentre study of SwiTching from Intravenous to subcutaneous inflixiMab and vEdolizumab in inflammatory bowel diseases: The TIME studyFerdinando D'Amico, Luca Massimino, Giulia Palmieri, et al.
European Journal of Gastroenterology & Hepatology|October 1, 2019
Late-onset Crohn's disease: a comparison of disease behaviour and therapy with younger adult patients: the Italian Group for the Study of Inflammatory Bowel Disease 'AGED' studyAnna Viola, Rita Monterubbianesi, Giuseppe Scalisi, et al.
Inflammatory Bowel Diseases|August 24, 2018
The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across ItalyAlessandro Armuzzi, Gionata Fiorino, Angela Variola, et al.
BMC Gastroenterology|July 5, 2023
SARS-CoV-2 infection in patients with inflammatory bowel disease: comparison between the first and second pandemic wavesCristina Bezzio, Marta Vernero, Stefania Costa, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|October 9, 2016
Disease patterns in late-onset ulcerative colitis: Results from the IG-IBD "AGED study"Walter Fries, Anna Viola, Natalia Manetti, et al.
Pageof 32

Showing results (291-300 of 320) with videos related to

Sort By:
Pageof 32
Journal of Clinical Medicine|January 8, 2025
Real-World Effectiveness and Safety of Selective JAK Inhibitors in Ulcerative Colitis and Crohn's Disease: A Retrospective, Multicentre StudyBernadett Farkas, Talat Bessissow, Jimmy K Limdi, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 21, 2013
Adalimumab in active ulcerative colitis: a "real-life" observational study, Alessandro Armuzzi, Livia Biancone, et al.
JAMA|July 22, 2024
Risankizumab for Ulcerative Colitis: Two Randomized Clinical TrialsEdouard Louis, Stefan Schreiber, Remo Panaccione, et al.
United European Gastroenterology Journal|November 18, 2020
Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD studyDaniela Pugliese, Giuseppe Privitera, Francesca Rogai, et al.
The American Journal of Gastroenterology|April 25, 2022
An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha InhibitorsSara Onali, Daniela Pugliese, Flavio Andrea Caprioli, et al.
European Journal of Clinical Investigation|July 9, 2024
An international multicentre study of SwiTching from Intravenous to subcutaneous inflixiMab and vEdolizumab in inflammatory bowel diseases: The TIME studyFerdinando D'Amico, Luca Massimino, Giulia Palmieri, et al.
European Journal of Gastroenterology & Hepatology|October 1, 2019
Late-onset Crohn's disease: a comparison of disease behaviour and therapy with younger adult patients: the Italian Group for the Study of Inflammatory Bowel Disease 'AGED' studyAnna Viola, Rita Monterubbianesi, Giuseppe Scalisi, et al.
Inflammatory Bowel Diseases|August 24, 2018
The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across ItalyAlessandro Armuzzi, Gionata Fiorino, Angela Variola, et al.
BMC Gastroenterology|July 5, 2023
SARS-CoV-2 infection in patients with inflammatory bowel disease: comparison between the first and second pandemic wavesCristina Bezzio, Marta Vernero, Stefania Costa, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|October 9, 2016
Disease patterns in late-onset ulcerative colitis: Results from the IG-IBD "AGED study"Walter Fries, Anna Viola, Natalia Manetti, et al.
Pageof 32